Skip to main content

Table 1 (abstract P133). Evaluation of clinical disease activity and safety aspects of patients with FMF

From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)

Efficacy parameters (total FMF cohort)

Baseline

12 months

24 months

Number of patients, N

74

46

24

Number (%) of patients in disease remission (physician rating)

22 (45)

23 (72)

12 (63)

Patient assessment of current disease activity; 0–10, median (min; max)

2.0 (0; 10)

2.0 (0; 7)

2.0 (0; 10)

Patient assessment of current fatigue; 0–10, median (min; max)

5.0 (0; 10)

2.0 (0; 10)

4.0 (0; 10)

AIDAI score <9 ≙ inactive disease, N (%)

12 (66.7)

14 (58.3)

8 (66.7)

CRP / SAA, median (mg/dl)

0.2 / 0.7

0.2 / 0.5

0.2 / 0.7

SAE (total FMF cohort)

Number of events

Incidence rate per 100 patient years

 

All types of SAE

18

14.03

 

SADR

2

1.56

 
  1. CRP, c-reactive protein; SAA, serum amyloid A; SADR, serious adverse drug reaction; SAE, serious adverse event